Table 2.
Immunotherapy therapy and clinical outcomes of advanced NSCLC patients with EGFR mutations
| Character | N (%) |
|---|---|
| Number of prior systemic regimens | |
| Median (range) | 4 (1–9) |
| Prior systemic therapy | |
| Targeted therapy | 31 (100%) |
| Chemotherapy | |
| No | 8 (25.8%) |
| Yes | 23 (74.2%) |
| Antiangiogenic therapy | |
| No | 8 (25.8%) |
| Yes | 23 (74.2%) |
| Local therapy | |
| No | 20 (64.2%) |
| Yes | 11 (35.5%) |
| Immunotherapy regimens | |
| Combination therapy | 25 (80.6%) |
| ICIs plus osimertinib | 1 (3.2%) |
| ICIs plus chemotherapy | 9 (29.0%) |
| ICIs plus antiangiogenic drugs | 9 (29.0%) |
| ICIs plus chemotherapy and antiangiogenic drugs | 6 (19.4%) |
| Monotherapy | 6 (19.4%) |